Treats CMV retinitis. ANDA 217267, held by Alembic. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 217267 (Valganciclovir Hydrochloride), held by Alembic, was first approved by FDA on Oct 26, 2026, with 0 approved supplements and 0 published complete response letters.
Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir Hydrochloride50MG/ML · for solution;oral | Valganciclovir Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters